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Ochratoxin A (OA), an important foodborne mycotoxin, is a potent teratogenic and nephrotoxic agent
produced by several species of Aspergillus and Penicillium. OA is a known inhibitor of protein synthesis via
competition with phenylalanine (Phe) in the phenylalanyl-tRNA synthetase-catalyzed reaction. It also has been
reported that a variety of toxic effects of OA can be prevented by Phe. This study was designed to determine
whether Phe could prevent or diminish the teratogenic effects of OA in rats. Pregnant Sprague-Dawley rats
were injected with a single individual dose ofOA (1.75 mg/kg) alone or in combination with a single dose of Phe
(20 mg/kg) or in combination with either a single or daily dose of Phe (25 mg/kg). OA dissolved in 5% sodium
bicarbonate and Phe dissolved in normal saline were administered subcutaneously on gestation day 7 to rats.
The incidences of OA-induced fetal malformations (gross and skeletal) were significantly diminished in the
presence of added Phe. These results indicate that coadministered Phe provides partial prenatal protection
from the teratogenic effects of OA.
Ochratoxin A (OA), a chlorinated dihydroisocoumarin
derivative connected through an amide bond to L-beta-
phenylalanine at the 7-carboxy group is an important food-
borne secondary metabolite produced by various species of
the fungal genera Aspergillus and Penicillium (16). It is a
potent nephrotoxin in a variety of animal species (12) and a
reported teratogen in rats (1, 14), mice (9), hamsters (10),
and chicken embryos (S. H. Gilani, J. Bancroft, and M.
O'Rahily, Teratology 11:18A, 1975). OA also has been
implicated as a causative factor in the fatal renal disease
endemic balkan nephropathy in humans (13).
OA inhibits protein synthesis by competition with the
amino acid phenylalanine (Phe) in the phenylalanyl-tRNA
synthetase-catalyzed reaction (2, 4). It has been reported
that Phe reverses OA-elicited cytotoxicity in tissue culture
(3), prevents the lethal effects of OA in mice (5), attenuates
OA inhibition of guinea pig macrophage migration (11), and
protects against the immunosuppressive effects of OA in
BALB/c mice (8).
The present study was undertaken to determine the effica-
cy of Phe in preventing or diminishing the teratogenic effects
of OA in rats.
MATERIALS AND METHODS
Sexually mature (175- to 200-g) virgin, Sprague-Dawley
female rats (Timco, Inc., Houston, Tex.) were maintained
on feed and water ad libitum at the Texas A&M University
Laboratory Animal Resources and Research Facility. After
an acclimation period of 1 week, 51 females were mated with
mature males of the same strain in filter-top, polycarbonate
cages housed in a temperature-controlled and artificially
illuminated room (12 h of light and 12 h of dark) free from
known sources of chemical contamination. The day on
which a vaginal plug was found was designated day 0 of
pregnancy.
Pregnant females were randomly distributed into seven
groups and treated as follows: group I, untreated; group II,
treated with solvent vehicles (5% sodium bicarbonate and
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saline); group III, Phe (25 mg/kg); group IV, OA (1.75 mg/
kg); group V, OA (1.75 mg/kg) plus Phe (20 mg/kg); group
VI, OA (1.75 mg/kg) plus Phe (25 mg/kg); and group VII, OA
(1.75 mg/kg) plus Phe (25 mg/kg) given once daily for the first
10 days of gestation. OA (Makor Chemicals, Ltd., Jerusa-
lem, Israel) dissolved in 5% sodium bicarbonate and L-beta-
phenylalanine (Sigma Chemical Co., St. Louis, Mo.) dis-
solved in normal saline (0.9% sodium chloride solution
adjusted to pH 7.2 with 0.1 M sodium hydroxide) were
administered subcutaneously on gestation day 7. All injec-
tion volumes were 0.1 ml/100 g of body weight. Six to nine
animals were used in each treatment group. Body weights of
pregnant rats were monitored daily.
Dams were euthanized by CO2 asphyxiation on day 20 of
pregnancy. The uterine horns were exposed, and the num-
bers of implants, resorptions, and live fetuses were counted.
Live fetuses were removed from the uterus, blotted dry,
weighed, and examined for gross abnormalities. Every third
fetus was fixed in 95% ethanol, cleared, and stained with
alizarin red S as described by Schnell and Newberne (15)
before examination for skeletal defects. The remaining fetus-
es were preserved in Bouin fluid for subsequent detection of
internal soft-tissue abnormalities by the method of freehand
razor sectioning as described by Wilson (17).
Data for fetal body weights, implantations, resorptions,
live fetuses, and percentage of malformed fetuses per litter in
each treatment group were analyzed statistically by Kruskal-
Wallis nonparametric analysis of variance and distribution-
free multiple-comparison tests (6, 7). In all statistical tests, P
< 0.05 was accepted as significant.
RESULTS
A single subcutaneous dose ofOA (1.75 mg/kg) injected on
gestation day 7 produced significant prenatal dysmorphogen-
esis in comparison with control animals. There was a signifi-
cant increase in the percentage of embryonic implants re-
sorbed. Approximately 72% of the implants were resorbed.
Fetal body weights also were decreased significantly (Table
1).
Phe did not exert any protective effects with regard to OA-
induced teratogenicity when coadministered with OA as a
single subcutaneous dose on gestation day 7 at levels less
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TABLE 1. Effect of Phe in rats treated with OA (1.75 mg/kg) on gestation day 7
No. No. of implants Resorptions Live fetuses Avg fetal
Treatment of lit- Total/ Average! Total! of i body weights
ters o er o % of Implants Total % of implants (g)tJgroup litter group group g
Group I (untreated) 7 84 12.0 ± 1.3a 5 5.4 ± 2.9a 79 94.6 ± 2.9a 3.73 ± 0.10a
Group lI (solvent treated) 7 85 12.4 ± 1.9a 2 2.1 ± 1.3a 83 97.9 ± 1.3a 3.92 ± 0.08a
Group III (Phe [25 mg/kg]) 6 78 13.0 ± 0.8a 6 7.2 ± 4.6a 72 92.6 ± 4.6" 4.00 ± 0.13a
Group IV (OA [1.75 mg/kg]) 8 110 13.8 ± 0.4a 79 71.8 ± 12.2b 31 28.2 ± 12.2b 2.69 ± 0.15b
Group V (OA [1.75 mg/kg] + Phe 9 113 12.6 ± 0.6a 59 52.2 9.5b 54 47.8 ± 9.5b 2.97 ± 0.12b
[20 mg/kg])
Group VI (OA [1.75 mg/kg] + 8 107 13.4 ± 1.la 49 46.0 ± 10.0b 58 54.0 ± 10.0b 2.66 ± 0.17b
Phe [25 mg/kg])
Group VII (OA [1.75 mg/kg] + 6 53 8.8 ± 1.9a 26 58.3 ± 13.2" 27 41.7 ± 13.2b 3.16 ± 0.28b
Phe [25 mg/kg] given daily for
the first 10 days of gestation
a.b Percent resorptions and live fetuses are based on the number of implants. Average and percent values are given as mean ± standard error of the mean. Group
means within a category which do not share the same superscript differ significantly from one another (P < 0.05); all such means which share the same superscript
do not differ significantly (P > 0.05).
than 20 mg/kg (data not shown). However, when Phe was
administered as a single dose of 20 mg/kg or as a single or
daily dose of as much as 25 mg/kg, the effect of OA on
embryos was diminished, but the decrease was not signifi-
cant when compared with rats treated with OA alone (Table
1). Approximately 52.0, 46.0 and 58.0% of implants were
resorbed in groups V, VI, and VII, respectively, versus 72%
in the group treated with OA alone. There was no significant
difference in fetal body weights between groups treated with
OA and Phe and the group treated with OA alone.
OA (1.75 mg/kg) induced significant gross, visceral, and
skeletal malformations (Table 2). The incidences of OA-
induced fetal malformations (gross and skeletal) were de-
creased significantly in the presence of Phe when compared
with rats treated with OA alone (Table 2). Rats treated with
OA in combination with Phe (20 mg/kg) had 26% grossly
malformed fetuses versus 61.3% in the group treated with
OA alone. Likewise, rats treated with OA in combination
with a daily dose of Phe (25 mg/kg) had only 42% of fetuses
with skeletal defects versus 100% in the group treated with
OA alone. The incidence of grossly malformed fetuses in
groups VI and VII and skeletal defects in groups V and VI
were decreased in the presence of Phe but were not statisti-
cally significant when compared with the group treated with
OA alone. OA-induced soft tissue defects were not de-
creased in the presence of Phe.
A comparison of percentages of specific fetal abnormali-
ties associated with prenatal exposure to OA with and
without Phe is presented in Table 3. Although the types of
OA-induced specific abnormalities remained similar in the
presence of Phe, the incidences of most of these abnormali-
ties, especially skeletal defects in group VII, were greatly
reduced.
Fetal development in animals treated with a single dose of
Phe (25 mg/kg) on gestation day 7, in the absence of OA,
appeared like untreated and solvent-treated controls (Tables
2 and 3).
DISCUSSION
OA is a very potent foodborne teratogen. It recently has
been demonstrated (14) that this mycotoxin results in signifi-
cant prenatal dysmorphogenesis after subcutaneous admin-
istration on gestation day 7 with a dose of only 1.75 mg/kg in
rats. Hence, this same treatment regimen was chosen to
initially characterize the antagonistic potential (regarding
OA-induced teratogenesis) of coadministered Phe.
OA has been reported to inhibit protein synthesis by
competition with Phe in the phenylalanyl-tRNA synthetase-
catalyzed reaction (2, 4). It also has been reported that a
variety of toxic effects of OA can be prevented by Phe (3, 8,
11). Most notably, Creppy et al. (5) have reported that the
simultaneous intraperitoneal administration of Phe in a sin-
gle dose slightly higher than the lethal dose of OA counter-
acted the acute lethal effects of OA in mice. Our results
TABLE 2. Rat litters with malformations from maternal exposure to OA (1.75 mg/kg) in combination with Phe on day 7
Malformations
External Visceral Skeletal
Treatment
No. ex- % Mal- No. ex- % Mal- No. ex- % Mal-
amined formed amined formed amined formed
Group I (untreated) 79 0.0" 52 0.0" 27 O.Oa
Group 1I (solvent treated) 83 0.0" 53 0.0" 30 3.3"
Group III (Phe [25 mg/kg]) 72 0.0" 43 0.0a 29 13.8"
Group IV (OA [1.75 mg/kg]) 31 61.3' 20 65.0b 11 100.0'
Group V (OA [1.75 mg/kg] + Phe 54 25.9b 34 70.6" 20 90.0'
[20 mg/kg])
Group VI (OA [1.75 mg/kg] + 58 48.3' 36 66.7b 22 90.9'
Phe [25 mg/kg])
Group VII (OA [1.75 mg/kg] + 27 37.0b"' 15 60.0" 12 41.7"
Phe [25 mg/kg] given daily for
the first 10 days of gestation)
a,b., Group means within a category which do not share the same superscript differ significantly from one another (P < 0.05); all such means which share the
same superscript do not differ significantly (P > 0.05).
VOL. 48, 1984
 o
n
 Septem
ber 11, 2018 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
APPL. ENVIRON. MICROBIOL.
TABLE 3. Fetal malformations associated with prenatal exposure
to OA (1.75 mg/kg) in combination with Phe on day 7
% of examined fetuses in:
Malformation Group Group Group Group
IV V VI VII
External
Anophthalmia 32.3 20.4 32.8 37.0
Hydrocephaly 54.8 16.7 32.8 25.9
Omphalocele 3.2 16.7 6.9 3.7
Ectopia cordis 9.3 3.4 3.7
Short snout 6.5 3.7 6.9
Hematoma 3.2 1.7
Micrognathia 3.2
Visceral
Hydrocephaly 65.0 70.6 55.6 46.7
Shift in position of esophagus 10.0 14.7 2.8 13.3
Skeletal
Bipartite sternebrae 36.3 40.0 40.9 16.7
Sternebrae agenesis 72.7 50.0 45.5 8.3
Bipartite vertebral centra 36.6 45.0 22.7 25.3
Vertebral centra agenesis 18.2 35.0 27.2
Incomplete ossification of 18.2 5.0 9.1
skull bones
Fused ribs 36.3 40.0 45.5 8.3
Missing ribs 15.0 31.8
Extra ribs 63.6 30.0 45.5
Wavy ribs 27.3
Broken ribs 9.1 5.0 9.1
Irregular arrangement of ribs 18.2 30.0 36.4
indicated that Phe, when administered at a dose in excess
(i.e., 11 to 14 times) of the minimum teratogenic dose of OA,
provides partial prenatal protection from this potent myco-
toxin. Moreover, multiple treatment with Phe appears to be
more efficacious with regard to antagonism of teratogenesis
than single-dose treatment and may indicate either a delay in
the delivery of OA or of active metabolite to a fetal site of
action or the necessity of threshold levels of Phe required to
prevent the teratogenicity of OA, or both.
The teratogenic mechanism of OA appears to be more
complex than the mechanism postulated for acute toxicity.
Although previous studies have attempted to correlate OA
toxicity with inhibition of Phe tRNA synthetase (8), our data
indicate that a Phe-directed site of action may be only
partially involved in the modulation of prenatal toxicity of
OA. Perhaps the antidotal activity of Phe may be further
enhanced via combination with other amino acids or conge-
ners. Clearly, dietary manipulation may hold the key to the
preventive toxicology of mycotoxins such as OA. Further
studies are now warranted to ascertain the ability of Phe to
prevent teratogenicity of OA via the diet.
ACKNOWLEDGMENTS
This work was supported in part by the Center for Comparative
Medicine Project 18820, TAES H 6215, Title XII AID CRSP 02-
50305-2, DOD Project DAAG29-83-G-0088, and AH 6647.
LITERATURE CITED
1. Brown, M. H., G. M. Szczech, and B. P. Purmalis. 1976.
Teratogenic and toxic effects of ochratoxin A in rats. Toxicol.
Appl. Pharmacol. 37:331-338.
2. Bunge, I., G. Dirheimer, and R. Roschenthaler. 1978. In vivo and
in vitro inhibition of protein synthesis in Bacillus stearothermo-
philus by ochratoxin A. Biochem. Biophys. Res. Commun.
83:398-405.
3. Creppy, E. E., A. A. J. Lugnier, G. Beck, R. Roschenthaler, and
G. Dirheimer. 1979. Action of ochratoxin A on cultured hepato-
ma cells-reversion of inhibition by phenylalanine. FEBS Lett.
104:287-290.
4. Creppy, E. E., A. A. J. Lugnier, F. Fasiolo, K. Heller, R.
Roschenthaler, and G. Dirheimer. 1979. In vitro inhibition of
yeast phenylalanyl-tRNA synthetase by ochratoxin A. Chem.
Biol. Interact. 24:257-261.
5. Creppy, E. E., M. Schlegel, R. Roschenthaler, and G. Dirheimer.
1980. Phenylalanine prevents acute poisoning by ochratoxin A
in mice. Toxicol. Lett. 6:77-80.
6. Gad, S. C., and C. S. Weil. 1982. Statistics for toxicologists, p.
273-320. In A. W. Hayes (ed.), Principles and methods of
toxicology. Raven Press, New York.
7. Gaylor, D. W. 1978. Methods and concepts of biometrics
applied to teratology, p. 429-444. In J. G. Wilson and F. C.
Fraser (ed.), Handbook of teratology, vol. 4. Plenum Publishing
Corp., New York.
8. Haubeck, H., G. Lorkowski, E. Kolsch, and R. Roschenthaler.
1981. Immunosuppression by ochratoxin A and its prevention
by phenylalanine. Appl. Environ. Microbiol. 41:1040-1042.
9. Hayes, A. W., R. D. Hood, and H. L. Lee. 1974. Teratogenic
effects of ochratoxin A in mice. Teratology 9:93-97.
10. Hood, R. D., M. J. Naughton, and A. W. Hayes. 1976. Prenatal
effects of ochratoxin A in hamsters. Teratology 13:11-14.
11. Klinkert, W., G. Lorkowski, E. E. Creppy, G. Dirheimer, and R.
Roschenthaler. 1981. Inhibition of macrophage migration by
ochratoxin A and citrinin, and prevention by phenylalanine of
the ochratoxin A-induced inhibition. Toxicol. Eur. Res. 3:185-
189.
12. Krogh, P., N. H. Axelsen, F. Elling, N. Gyrd-Hansen, B. Hald, J.
Hyldaard-Jensen, A. E. Larsen, A. Madsen, H. P. Mortensen, T.
Moller, 0. K. Petersen, U. Ravnskov, M. Rostgaard, and 0.
Aalund. 1974. Experimental porcine nephropathy. Acta Pathol.
Microbiol. Scand. Sect. A Suppl. 246:1-21.
13. Krogh, P., B. Hald, R. Plestina, and S. Ceovic. 1977. Balkan
(endemic) nephropathy and food-borne ochratoxin A: prelimi-
nary results of a survey of food stuffs. Acta Pathol. Microbiol.
Scand. Sect. B 85:238-240.
14. Mayura, K., R. V. Reddy, A. W. Hayes, and W. 0. Berndt. 1982.
Embryocidal, fetotoxic and teratogenic effects of ochratoxin A
in rats. Toxicology 25:175-185.
15. Schnell, V., and J. W. Newberne. 1970. Accelerated clearing and
staining of teratologic specimens by heat and light. Teratology
3:345-348.
16. Scott, P. M., W. Van Walbeek, B. Kennedy, and D. Anyeti. 1972.
Mycotoxins (ochratoxin A, citrinin and sterigmatocystin) and
toxigenic fungi in grains and agricultural products. J. Agric.
Food Chem. 20:1103-1109.
17. Wilson, J. G. 1965. Methods for administering agents and
detecting malformations in experimental animals, p. 262-277. In
J. G. Wilson and J. Warkany (ed.), Teratology: principles and
techniques. University of Chicago Press, Chicago.
1188 MAYURA ET AL.
 o
n
 Septem
ber 11, 2018 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
